Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis

被引：31

作者：

Crommentuyn, KML

Mulder, JW

Sparidans, RW

Huitema, ADR

Schellens, JHM

Beijnen, JH

机构：

[1] Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands

[2] Slotervaart Hosp, Dept Internal Med, NL-1066 EC Amsterdam, Netherlands

[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[4] Univ Utrecht, Fac Pharmaceut Sci, Dept Biomed Anal, Div Drug Toxicol, NL-3508 TC Utrecht, Netherlands

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 38卷 / 08期

关键词：

D O I：

10.1086/382675

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis. Coadministration of these agents led to a strong increase in itraconazole concentrations and a decrease in concentrations of its metabolite, hydroxyitraconazole, which is equally active pharmacologically. The dosage of itraconazole was reduced when it was used in combination with lopinavir/ritonavir.

引用

页码：E73 / E75

页数：3

共 11 条

[1]

Bertz R, 2000, AIDS, V14, pS100

[2] Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry [J].